PTPRC and metastatic malignant neoplasm: Notably, our findings in the metastatic cancer model demonstrated that enhanced T effector responses in MTR OralGem-treated mice were associated with increased antigen-presenting functions on tumor-infiltrating DCs, as evidenced by increased percentages of CD45+CD11c+ cells expressing the costimulatory molecule, CD80.